Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

類似資料

• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
  著者:: Li, Yang-Ling, 等
  出版事項: (2018)
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
  著者:: Pan, Yong-hong, 等
  出版事項: (2018)
• Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
  著者:: Yan, Han, 等
  出版事項: (2015)
• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
  著者:: Costa, Daniel B., 等
  出版事項: (2008)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  著者:: Nishino, Mizuki, 等
  出版事項: (2016)